X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs FULFORD INDIA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD FULFORD INDIA ORCHID PHARMA LTD/
FULFORD INDIA
 
P/E (TTM) x -0.2 398.8 - View Chart
P/BV x 0.1 6.2 2.1% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 ORCHID PHARMA LTD   FULFORD INDIA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
FULFORD INDIA
Mar-14
ORCHID PHARMA LTD/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs194942 20.6%   
Low Rs35450 7.8%   
Sales per share (Unadj.) Rs276.5691.4 40.0%  
Earnings per share (Unadj.) Rs-79.211.5 -691.1%  
Cash flow per share (Unadj.) Rs-43.515.4 -282.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs53.9380.0 14.2%  
Shares outstanding (eoy) m70.453.90 1,806.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.41.0 41.1%   
Avg P/E ratio x-1.460.7 -2.4%  
P/CF ratio (eoy) x-2.645.3 -5.8%  
Price / Book Value ratio x2.11.8 115.9%  
Dividend payout %017.4 0.0%   
Avg Mkt Cap Rs m8,0672,714 297.2%   
No. of employees `0002.80.4 630.6%   
Total wages/salary Rs m2,527505 500.4%   
Avg. sales/employee Rs Th6,956.16,073.0 114.5%   
Avg. wages/employee Rs Th902.51,137.4 79.3%   
Avg. net profit/employee Rs Th-1,993.0100.7 -1,979.6%   
INCOME DATA
Net Sales Rs m19,4772,696 722.3%  
Other income Rs m407125 324.7%   
Total revenues Rs m19,8842,822 704.7%   
Gross profit Rs m1,103-46 -2,376.3%  
Depreciation Rs m2,51915 16,573.7%   
Interest Rs m5,22710 55,018.9%   
Profit before tax Rs m-6,23654 -11,484.7%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-12510 -1,304.2%   
Profit after tax Rs m-5,58045 -12,483.9%  
Gross profit margin %5.7-1.7 -329.0%  
Effective tax rate %2.017.7 11.4%   
Net profit margin %-28.71.7 -1,728.3%  
BALANCE SHEET DATA
Current assets Rs m11,0141,738 633.6%   
Current liabilities Rs m32,060545 5,885.9%   
Net working cap to sales %-108.144.3 -244.1%  
Current ratio x0.33.2 10.8%  
Inventory Days Days9548 195.8%  
Debtors Days Days344 779.5%  
Net fixed assets Rs m29,44012 247,394.1%   
Share capital Rs m70539 1,806.4%   
"Free" reserves Rs m2,0431,443 141.6%   
Net worth Rs m3,8001,482 256.4%   
Long term debt Rs m9,0180-   
Total assets Rs m46,5102,077 2,239.6%  
Interest coverage x-0.26.7 -2.9%   
Debt to equity ratio x2.40-  
Sales to assets ratio x0.41.3 32.3%   
Return on assets %-0.82.6 -29.1%  
Return on equity %-146.93.0 -4,868.8%  
Return on capital %-3.74.3 -86.8%  
Exports to sales %37.90-   
Imports to sales %22.624.5 92.5%   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406659 668.3%   
Fx inflow Rs m7,51317 43,682.0%   
Fx outflow Rs m5,649673 839.1%   
Net fx Rs m1,865-656 -284.2%   
CASH FLOW
From Operations Rs m1,68290 1,868.6%  
From Investments Rs m-9,860105 -9,426.8%  
From Financial Activity Rs m6,644-14 -47,119.1%  
Net Cashflow Rs m-1,535181 -850.4%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 3.8 121.1%  
FIIs % 3.3 0.1 3,300.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 21.2 260.8%  
Shareholders   84,811 4,783 1,773.2%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Apr 18, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 8-QTR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS